Finance

Beta
Lists
BALAXI:NSE
Balaxi Pharmaceuticals Ltd
₹24.50
-0.61%
(-0.15) 1D
Jun 5, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for BALAXI...
Open
₹24.53
High
₹24.98
Low
₹24.13
Mkt. cap
1.34B
Avg. vol.
36.36K
Volume
21.84K
P/E ratio
94.23
52-wk high
₹63.90
52-wk low
₹15.20
EPS
₹0.26
No. of employees
600
Open
₹24.53
High
₹24.98
Low
₹24.13
Mkt. cap
1.34B
Avg. vol.
36.36K
Volume
21.84K
P/E ratio
94.23
52-wk high
₹63.90
52-wk low
₹15.20
EPS
₹0.26
No. of employees
600
News stories
From sources across the web
About Balaxi Pharmaceuticals Ltd
CEO-
Employees600
Founded1942
Headquarters-
SectorHealth care provider
Websitebalaxipharma.in
Last report
May 28, 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
- / -
Revenue / Est. (INR)
707.14M / -
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
707.42M
561.75M
725.42M
707.14M
Cost of goods sold
395.60M
290.29M
417.35M
405.51M
Cost of revenue
395.60M
290.29M
417.35M
405.51M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
270.34M
259.77M
277.18M
300.41M
Operating expense
274.96M
264.62M
282.77M
306.88M
Total operating expenses
670.56M
554.91M
700.12M
712.38M
Operating income
36.86M
6.84M
25.30M
-5.25M
Other non operating income
-17.76M
15.85M
957.00K
29.17M
EBT including unusual items
9.03M
13.77M
16.10M
14.02M
EBT excluding unusual items
9.03M
13.77M
16.10M
14.02M
Income tax expense
6.13M
11.68M
13.05M
7.90M
Effective tax rate
67.89%
84.82%
81.05%
56.31%
Other operating expenses
-
-
-
-
Net income
2.90M
2.09M
3.05M
6.13M
Net profit margin
0.41%
0.37%
0.42%
0.87%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-10.06M
-8.92M
-10.16M
-9.90M
Net interest expenses
-10.06M
-8.92M
-10.16M
-9.90M
Depreciation and amortization charges
4.62M
4.84M
5.60M
6.46M
EBITDA
41.13M
11.58M
29.57M
134.25K
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer